Europabio

EuropaBio Patient BioForum: Advancing patient access to innovative treatments
2021-05-18 10:30 - 14:30 (Europe/Brussels)
2021 is set to be another landmark year in the area of health. It is hoped to not only relieve the burden of the COVID-19 pandemic on EU patients and healthcare systems, but also let the health community advance the great number of other priorities there are. In the EU, 2021 is set to give a start to the implementation of the European Health Union and the related objectives of the new EU Pharmaceutical Strategy. Among these, the EU health community is looking to improve patients’ access to therapies for challenging and rare conditions.

This meeting of EuropaBio’s Patient BioForum will discuss avenues for enhancing the access of EU patients to novel biotechnology-derived treatments in two sessions:

Morning session – 10:30-12:00 CET

Pharmaceutical Strategy implementation for continued innovation and delivery in the area of rare and paediatric diseases.

The European Commission is discussing on the calibration of incentives for investing in the development of medicines for rare and paediatric diseases both with Member States and stakeholders. We invite the BioForum members to exchange proposals for informing this important debate on several key points, such as criteria for defining unmet need and incentivising innovation in such areas, etc.

Afternoon session – 13:00-14:30 CET

Improving patient access across borders

The EU Directive on cross-border healthcare is an important instrument to ensure patient access to the best available care. The Directive is particularly relevant for advanced therapies and medicines for rare diseases. Well-functioning EU cross-border healthcare legislation can ensure patients have access to specialised treatments and novel therapies when these are not available in their home country.

The exchange between guest speakers and BioForum members is aimed to result in the post-meeting release of policy recommendations for how patient access can be advanced in the EU in the context of its new Pharmaceutical Strategy.

We very much look forward to your active participation on 18 May 2021.

VIRTUAL EVENT

Renewable Materials Conference
2021-05-18 09:00 - 2021-05-20 17:00 | NovaInstitute, Chemiepark Knapsack Industriestraße 300, Huerth, 50354, Germany
Featuring a unique concept to present all sustainable and renewable material solutions at one event: bio-based, CO2-based and recycled. This time, the conference will be held as hybrid event. 300 to 400 participants are expected.

There is a growing market demand for advanced and ready-to-use sustainable material solutions with a low carbon footprint – and fossil-free. As a response to this challenge, nova-Institute has decided to unite all relevant industries in the new Renewable Materials Conference (RMC). Over three days, participants get a complete overview of the latest renewable material solutions from a wide range of sustainable raw materials and technologies.

The first day will be focusing on building blocks and chemicals, the second on polymers and plastics and the third on plastic and composite materials. Or in other words: All material solutions based on renewable carbon – avoiding the use of additional fossil carbon.

The Renewable Materials Conference is the follow-up event to the “13th International Conference on Bio-based Materials”, which builds on a successful history of previous conferences: In 2019, more than 270 participants attended and 30 exhibitors were present. It was the second largest event on bio-based materials in Europe and continues within this new concept. The conference also integrates topics from the “Biocomposites Conference Cologne” and extends the conference with presentations on chemicals and polymers from CO2 use (CCU) as well as new solutions from the field of recycling, so that the entire spectrum of renewable materials is covered.

nova-Institute’s renewable carbon approach aims to initiate the end of the fossil age of chemicals and plastics and builds the foundation for the RMC. Renewable chemicals, plastics, composites, fibres and other products can be produced either from biomass, directly via CO2 utilisation, or recycling. Naturally, this includes the established areas of bio-based polymers and biocomposites.

The conference will help shape the sustainable future of chemicals and materials and will provide new advantages and synergies by establishing a meeting point for numerous cross-sectoral networking opportunities.

Taking health up a gear: value of advanced therapies
2021-05-11 12:00 - 13:00
Advanced therapies have ground-breaking therapeutic potential, particularly in disease areas where there is an unmet medical need and available therapeutic options are absent or inadequate. These therapies can bring the possibility of a cure to life-threatening conditions with a one-off treatment, thereby changing the paradigm of providing health and care to patients suffering serious, rare or complex diseases.

A breakthrough innovator in the area of rare diseases will explain the cutting-edge science behind gene therapies, why they are considered so transformative, and what promise they hold to addressing unmet patient needs.

A leading developer of the most innovative cancer treatments – CAR-T cell-based therapies will explain the changing paradigm of providing health for cancer patients and how innovation will help achieve the objectives of Europe’s Beating Cancer Plan.

The webinar will also engage policy makers reflecting live on how EU policies can truly harness the ground-breaking potential of advanced therapies.

Speakers

Sara Cerdas MEP, BECA

Dick Sundh, Head of ACE (Australia, Canada & Europe) at Kite Pharma, a Gilead Company

Dirk Vander Mijnsbrugge, Vice President Medical Affairs Lead Rare Diseases International Developed Markets at Pfizer

Simone Boselli, Public Affairs Director at EURORDIS

About EuropaBio Advanced Therapies Series:

The EuropaBio Advanced Therapies series of events, interviews, and publications will engage policymakers, regulators, patients and their representatives, developers, and all relevant stakeholders to discuss how innovation in gene- and cell-based medicine can bring a transformative value for patients.

Throughout 2021, we invite you to join us on a journey of exploring the tremendous potential of advanced therapies by discussing the new treatment paradigms, the future of research and development in this fast-moving space of bio-science, as well as debating recommendations for improving the access of patients to these ground-breaking treatments and supporting advanced manufacturing, to name a few.

VIRTUAL EVENT

REGISTER HERE

Building on biotechnology: From vaccines to economic growth for Europe
2021-05-10 15:00 - 18:00
EuropaBio National Associations Council

Summit 2021 – Portugal

EuropaBio’s National Associations Council (NAC) is a platform that brings together all EuropaBio’s National Associations and helps to ensure coordination of EuropaBio actions throughout Europe. The NAC represents biotechnology priorities across Europe’s Member and partner countries, working together to build long term economic and societal benefit from biotechnology across sectors.

In 2021, the NAC is proud to host its first Summit focussed on priorities for commercial biotechnology development, delivering the Industrial Strategy within national and European ecosystems.

The NAC summit on May 10 will address how we learn from the COVID-19 response, to enable full societal and economic benefit from biotechnology in the future across sectors. Rapid technology development pathways, including partnering, investment and approvals, created in response to the pandemic have created new, faster routes to market. Although this was a unique scale and speed for vaccine development, it shows that biotech can perform quickly and strongly to address unmet issues in healthcare and sustainable development, creating a solution and also supporting economic recovery across Europe.

The EuropaBio NAC Summit is held during the Portuguese Presidency of the Council of EU and organized in collaboration with P-BIO. The outcomes from the Summit will include a EuropaBio NAC Position on building economic pathways from biotech post-Covid with the role of aligned and ambitious national policies and actions.

Agenda

15:00: Welcome – Claire Skentelbery, Director General, EuropaBio

15:05: Opening remarks – Manuel Heitor, Minister of Science, Technology and Higher Education, Portugal

15:15: A European ambition in a competitive global landscape.

Where biotech and economic ambitions sit within European and global strategies – Claire Skentelbery, Director General, EuropaBio

15:30: Session 1 – A new biotechnology ecosystem in Europe

Companies active in the current response to Covid-19 share how they have built vital collaborations across the biotech-pharma spectrum to deliver breakthrough vaccine technologies to patients at unprecedented speed, plus how they envision future potential.

15:30: Economic development driven by Biotech – the Portugal perspective: David Malta, Founding CEO, LiMM Therapeutics

15:45: Developing bio-manufacturing partnerships – Elke Grooten, Head of EU Relations, Novartis

16:00: Pharma-SME collaboration: from innovation to patient, a global journey – Sinan Atlig, Regional President IDM, Vaccines Pfizer

16:15: Break

16:30: Session 2 – Looking to the future – speed and strength from biotech

SMEs driving next generation biotechnology present the pathway and challenges to success and highlight what Europe needs to achieve. EuropaBio National Associations will then discuss the critical framework needed to build further from national and European ecosystem advances from Covid, accelerating biotech contribution to Europe’s economic development.

SME drivers

16:30: The future of vaccines – Bruno Santos, Co-Founder and CEO, IMMUNETHEP

16:40: Reaching all patients for immunity – Kim Kjøller, CEO, UNION Therapeutics

Building European strengths

16:50: Discussion Panel – Associations from across Europe plus audience contributions

Moderator: Claire Skentelbery

Panellists:

– Agne Vaitkeviciene, Executive Director, Lithuanian Biotechnology Association

– Chloe Evans, Market Research Manager & International Relations, France Biotech

– Simão Soares, President, P-BIO

– Hanne Mette Dyrlie Kristensen, CEO, The Life Science Cluster (Norway)

18:00: Summary and Close

VIRTUAL EVENT

REGISTER HERE

Who should attend?

The EuropaBio NAC Summit is open and free of charge. You should attend if you are active within the development of biotechnology ecosystems at national or European levels, either as a technology stakeholder (academic or industrial) or a facilitator of technology maturation to market and patients (associations, tech transfer, investors, policy makers…). The event will have a strong discussion element and all participants can be actively involved. The event will also develop preparatory statements for delegate feedback plus post-event discussion on the planned NAC Position.

Download below the speakers’ presentations:

EuropaBio-NAC-Summit-10-May-2021-Slides-FINAL-PDFDownload

German Corona Showcase
2021-04-28 09:00 - 2021-04-30 17:00
A considerable part of the global activities for the development and production of diagnostics, vaccines and drugs against Covid-19 takes place at biotech sites in German-speaking countries.

The e-Vent will…

Give the opportunity to discuss funding, procurement and governmental supportGive the opportunity to exchange an discuss experiences made with corona researchProvide industry insights and expert views for press representatives and government employee

VIRTUAL EVENT

EU Industrial Biotech Policy Priorities for SMEs
2021-04-22 14:00 - 15:00
Join the EuropaBio Industrial Biotechnology Team for a dive into EU policies that impact your current operations and will shape your future strategies. With the Green Deal, Industrial Strategy, Circular Economy and many more, SMEs can take advantage of changes and opportunities to plan and grow their business.

About the EuropaBio SME Platform

The SME platform is a community of SMEs across all sectors in Europe, supported through regular online meetings around EU-level topics that impact commercial biotechnology and represented to EU stakeholders.

REGISTER HERE

Think, Act, EUnite: A post-COVID-19 paradigm shift in European healthcare
2021-04-22 09:00 - 10:15
A PUBLIC webinar sponsored by the Novartis EUnite4Health Ecosystem Team

For citizens, industry, and institutions, COVID-19 was a stress test that revealed faults in our current health ecosystem. From a less-than-optimal regulatory review and approval processes which limit patient access, to an industrial manufacturing network that could be improved, and an R&D ecosystem that is not achieving its full potential, we have collectively witnessed a health ecosystem ready for evolution.

As Europe looks to adopt the “lessons learned” from this crisis, now is an opportune moment to create change, discuss opportunities, and build a future-ready health policy.

On behalf of EuropaBio, JA Europe, and Novartis, we are pleased to share a save the date for our Think, Act, EUnite: A post-COVID-19 paradigm shift in European healthcare, PUBLIC webinar to discuss what the future of healthcare in Europe could look like.

Confirmed speakers include:

Tomislav Sokol, Member of the European Parliament (EPP, Croatia)

Seán Kelly, Member of the European Parliament (EPP, Ireland)

Irene Norstedt, Director, People, DG Research and Innovation (RTD), European Commission

Mary Harney, Former Irish Minister of Health

Bettina Ryll, Member of the European Commission’s Cancer Mission Board, Physician and Founder of Myeloma Patient Network Europe

Claire Skentelbery, Director-General of EuropaBioKees Roks, Head of Region Europe, Novartis Oncology and Member of the European Commission’s Cancer Mission Assembly

Virtual Event

Register here

Nordic Life Science Days
2021-04-19 09:00 - 2021-04-21 17:00 | SwedenBIO, Wallingatan 24, Stockholm, 111 24, Sweden
Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. Most attendees express their delight in the informal atmosphere, combined with an organised approach to meeting highly relevant people. Return visitors come back because they feel they belong to our growing community.

We hope to welcome you in Digital format too. We will create live and virtual spaces for meaningful encounters, with one-on-one meetings being one of the main features of NLSDays. Additionally, the high quality of topics and presenters provide insight into the most recent trends in science and business.

NLSDays attracts leading decision makers from biotech, pharma and medtech as well as finance, research, policy and regulatory authorities.

VIRTUAL EVENT

An EU Vision for Life Science and Biotechnology for a Healthy and Sustainable EU
2021-04-15 13:00 - 14:30
With the ambitious target to cut greenhouse gas emissions by 55% compared to 1990 levels by 2030 and the EU Green Deal, the EU has set clear goals to transform the bloc´s economy making it more sustainable while supporting the EU recovery.

Life sciences and biotechnology remain critical key-enabling technologies for the economy, generating GDP of over €34.5 billion, employing 223,000 people directly in the EU and generating a trade surplus of €22 billion in 2018. Moreover, the CO2 mitigation potential of industrial biotech is estimated between 1-2.5 billion tonnes of CO2 equivalent per year by 2030.

The Danish life science and biotechnology contributed to the local economy with over €14 billion export of goods and employing around 48,000 jobs in 2019. Given the importance of this sector for the Danish economy, the government is working on a new political strategy for the life science sector to succeed the sector’s growth plan implemented in March 2018.

The current COVID-19 pandemic has highlighted the need to employ a holistic and strategic approach and exploit synergies among various EU policies, such as in the areas of research and innovation, industry and health. Furthermore, it showed us that the speed at which technologies develop requires that legislation is constantly up-to-date and able to embrace new sustainable innovation. Investing in the transition to a new sustainable economy requires modernised legislation that can support the green transition in the Member States and support the advancement of the EU life science and biotechnology to ensure they continue their main purpose to support the European Union’s ambitious agenda for healthy people and healthy planet.

VIRTUAL EVENT

Innovation for Health - Shaping the Future of Healthcare
2021-04-15 09:00 - 2021-04-16 17:00 | VIRTUAL, Hyphen Projects - Veerstraat 37, Hilversum, 1211 HJ, Netherlands
On 15-16 April 2021, the 8th edition of Innovation for Health takes place as an online edition with hybrid aspect. Innovation for Health is the meeting place where over 900 bright minds from across Health and Life Sciences come together to shape the future of healthcare. The theme of this year’s conference is immunology, a topic that, because of the COVID-19 pandemic, has never been more relevant. With our energizing programme, we bring over 40 top-notch speakers to the stage, display high impact innovations, highlight best practices, and demonstrate inspiring developments in healthcare. Inspiring, interacting, and networking are at the heart of the conference. Innovation for Health is the leading conference for key players in Health & Life Sciences.

VIRTUAL EVENT

All About RC(I) – Discussing the Renewable Carbon Strategy and Initiative
2021-04-07 14:00
Discuss the concept of renewable carbon and get answers to all your questions. Get to know the people and companies behind the Renewable Carbon Initiative and learn why your company should join. RCI members Cosun and UPM and nova-Institute will discuss and answer your questions.

About the organizers

The Renewable Carbon Initiative (RCI) was initiated by nova-Institute after observing the struggles of the chemical and plastics industry facing the enormous challenges in meeting the climate goals set by the European Union and the sustainability expectations held by societies around the globe. It was clear that the industry has to go beyond using renewable energy. As decarbonisation is not an option for organic chemistry, which is entirely based on the use of carbon, an alternative strategy was needed.

VIRTUAL EVENT

9th Conference on CO2-based Fuels and Chemicals
2021-03-23 09:00 - 2021-03-24 17:00 | NovaInstitute, Chemiepark Knapsack Industriestraße 300, Huerth, 50354, Germany
The conference is one of the oldest and most established worldwide and has developed into a unique meeting place for the entire Carbon Capture & Utilisation (CCU) and Power-to-X industry and its customers.

The first day will focus on CO2-based transport and aviation fuels, the second on CO2-based bulk and fine chemicals. CCU technologies are essential to meet the future demand for carbon from renewable sources. Take a look into the near future and exchange ideas with the leading pioneers.

CCU is one essential pillar for the supply of renewable carbon besides biomass and recycling. The transition to direct CO2 utilisation as one alternative carbon source is needed to substitute fossil sources, to fight climate change and to shift towards sustainable and climate-friendly production and consumption. For providing the full benefits of CCU technologies the use of renewable energy is indispensable. Especially the supply of green hydrogen is crucial for the production of CO2-based transportation and aviation fuels, bulk and fine chemicals.

A large number of European cross-sectoral projects for hydrogen production via large-scale electrolysers have been announced recently. The European Commission launched a 400 Billion hydrogen strategy for the full energy transition to renewable energies, as well as for the further use of hydrogen in innovations and technologies such as the production of high-volume synthetic fuels and chemicals.

Meanwhile, 100 projects on CO2-based fuel and chemical production, as well as efficient capture and utilisation technologies have been launched by several start-ups and established companies, ranging from pilot over demonstration to commercial scale. Even more players show their interest in getting involved in CCU and are increasingly planning and implementing more plants on different scales for Power-to-X technologies, low carbon fuels and a CO2-based chemistry. Great visions are becoming real business cases and innovations are starting to realise their potential!

New and leading players will showcase novel and improved applications based on the use of CO2 as feedstock. Main topics of the conference are green hydrogen production, carbon capture technologies and carbon utilisation (Power-to-X): Transportation and aviation fuels, building-blocks, bulk and fine chemicals as well as advanced technologies for CO2 utilisation such as artificial photosynthesis.

BIO-Europe Spring 2021
2021-03-22 09:00 - 2021-03-25 17:00
The “must-attend” event series has gone digital, and continues to grow from strength to strength, proving its importance and relevance to the life science sector. Building on the success and momentum created by BIO-Europe Digital 2020 this past October our upcoming BIO-Europe Spring Digital will deliver more licensing opportunities, more partnering meetings, and more hot-off-the-press content than ever.

Here’s what will be different for 2021:

PRE-RELEASED CONTENT. The digital event will open 5 weeks early with on-demand content (panels, company presentations and company showcases) to complement your partnering preparations and maximize your digital experience. partneringONE ALL in ONE. Our gold standard partnering platform has been transformed for the virtual era! With ONE login, you access the entire event. No need to switch back and forth between platforms. Search by company or therapeutic area to discover potential partners and relevant conference sessions and company presentations.ONE SCHEDULE. To satisfy a truly global audience made up of thousands of delegates from more than 55 countries, we provide one schedule that accommodates ALL TIME ZONES. SOCIAL NETWORKING OPPORTUNITIES. We understand the value of networking outside of one-to-one meetings. In order to fill that void, we created the “W

KeyGene’s two-part webinar on PanGenomes: needs, value and applications (part 2)
2021-03-18 16:00 - 17:00
This two-part webinar on PanGenomes, which Keygene organizes together with an academic partner and Allen Sessions from BASF, will explain what one needs to construct PanGenomes and highlight their value in breeding and research. PanGenomes describe the available genetic diversity within, for instance, plant species, crops or germplasm collections. Because of diminishing costs of genome sequencing, increasing speed of reference genomes construction and advances in bioinformatics, PanGenomes have become an accessible tool. The genome insights delivered by PanGenomes can spectacularly speed up and contribute to plant breeding and research.

#EUIndustryWeek2021: BIO NRW
2021-03-18 11:00 - 15:45
Driving Change – How Green Chemistry and Digitalisation lead the way to a Sustainable EconomyThe focus of their event is green chemistry and sustainable processes, focusing on how biotechnology and digitalization can contribute to the green transition. Watch the intervention from EuropaBio on on the EU perspective and what the industry suggests to drive innovation forward on the first day.

Empowering the Circular Bioeconomy through the EU Green Deal
2021-03-17 14:00 - 16:00 | VIRTUAL, Rue de la Science 10, Brussels, 1000, Belgium
The 2020 Circular Economy Action Plan is one of the main blocks of the European Green Deal – Europe’s new agenda for sustainable growth – including initiatives along the entire life cycle of products and aiming at rendering sustainable products the norm in the EU. It focuses on boosting circular economy processes, fostering sustainable consumption, and safeguarding that the resources used are kept in the economy for as long as possible. In addition, it remains committed to making circularity work for people, regions, and cities, while leading global efforts on circular economy.

At the same time, and closely linked with the above, the bioeconomy offers great potential in contributing to tackle environmental and societal challenges, such as resource efficiency, climate change, maintaining European competitiveness and job creation. The bioeconomy can therefore play a significant role in the EU Green Deal and particularly in the transition to a circular economy, as outlined in a position paper developed by the European Bioeconomy Alliance. As a result, this webinar aspires to address the above developments by providing an opportunity for discussion of how to best empower the circular bioeconomy through an enabling policy framework.

Event hosted by MEP Franc Bogovič, Chair of the Bioeconomy Working Group of the European Parliament Intergroup on ‘Climate Change, Biodiversity and Sustainable Development’.

VIRTUAL EVENT

All About RC(I) – Discussing the Renewable Carbon Strategy and Initiative
2021-03-10 14:00 | Virtual Event

Immunology Virtual Partnering (Member Discount)
2021-03-09 09:00 - 2021-03-12 17:00 | VIRTUAL, 89 Rue Tronchet, Lyon, 69006, France
Over 4% of the world’s population suffers from one or more of the over 80 autoimmune diseases identified to date. A large variety of treatment approaches have already been developed to curb the detrimental effects of autoimmune diseases, and the market continues to flourish. In fact, by 2025 this market is estimated to exceed a global value of $150 billion.

At Inova, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO), in partnership with Evaluate, are organizing this Immunology Virtual Partnering Event. Through online one-to-one meetings taking place 9-12 March, researchers, biotechs and biopharmaceutical companies will discuss the latest research from immunology congresses, pitch ideas and partner to prioritize the most promising research efforts.

This event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide.

EuropaBio Members can benefit from a 15% discount. Please liaise with Martina Cilia for further details.

VIRTUAL EVENT

Measuring the Economic Footprint of the Biotechnology Industry in Europe
2021-03-04 14:00 - 15:30
Landscape and Positions for Economic Development: Industry and policy discussions to deliver biotechnology in Europe.

European GDP benefitted by €38.5 bn in 2018, in the recent study from EuropaBio ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’. The study looked at the economic impact of the biotechnology industry within the (then) 28 European member states, in terms of gross value added (GVA), employment and trade. Including spill over effects, that number rises to €78.7bn. The direct contribution adds up to about 1.5% of total industrial GVA within the countries assessed, supported by 223,000 direct jobs rising to over 700,000 with associated employment.

Very few other sectors enhance quality of life, knowledge, innovation, productivity, andenvironmental protection as biotechnology does.

Join EuropaBio on March 4 to find out more about the the economic footprint of biotechnology in Europe and be part of the discussion on its role in future economic recovery and delivering healthy people and planet.

Annual Conference on EU Law in the Pharmaceutical Sector
2021-03-03 08:45 - 12:15 | VIRTUAL, Metzer Allee 4, Trier, D-54295, Germany
Annual Conference on EU Law in the Pharmaceutical Sector (3-5 March 2021)

Objective

This online conference will bring legal practitioners working with the pharmaceutical sector up-to-date on the latest relevant regulatory developments, legislative initiatives and case law.

Key topics

Impact of recent rulings from the CJEU on supplementary protection certificates, patent settlements, and online sales of medicinal products Ongoing European Commission cases on competition lawTowards a European Health Data SpaceThe European Commission’s Pharmaceutical StrategyInitiatives related to Covid-19: shortage of medicines, dependency on raw materials from outside the EU, cooperation between Member StatesFair competition between pharmaceutical companies in times of Covid-19 and Brexit

Who should attend?

In-house counsel, lawyers in private practice, lawyers in national ministries and authorities dealing with regulation of the sector.

Interactive online event

The conference will be hosted on ERA’s own online platform. You will be able to interact immediately and directly with our top-level speakers and other participants. We will make the most of the technical tools available to deliver an intensive, interactive experience. As the platform is hosted on our own server, the highest security settings will be applied to ensure that you can participate safely in this high-quality online conference.

Networking

Networking opportunities where participants can meet each other and chat with speakers will be offered.

EuropaBio Members can benefit of a 25% discount on the price. Please liaise with Martina Cilia (m.cilia@europabio.org) to receive detailed information on the discount code.

Oncology Virtual Partnering (Member Discount)
2021-03-02 09:00 - 2021-03-05 17:00 | VIRTUAL, Inova Software, 89 Rue Tronchet, Lyon, 69006, France
Oncology is one of the most challenging areas for research and development, but there are critical junctures where the right environment is crucial for success – and where partnering can help bring the best science forward.

At Inova, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO), in partnership with Evaluate, are organizing this Oncology Virtual Partnering Event. Through online one-to-one meetings taking place 2 – 5 March, researchers, biotechs and biopharmaceutical companies will discuss the latest research from oncology congresses, pitch ideas and partner to prioritize the most promising research efforts.

This event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide.

EuropaBio Members can benefit from 15% discount. Please liaise with Martina Cilia for further details.

1st International Conference on Rare Diseases
2021-03-01 09:30 - 2021-03-02 17:00 | VIRTUAL, 338. Kleisthenous Str., Gerakas, Attiki, 15344, Greece
1st International Conference on Rare Diseases

Different infrastructures and organisational arrangements are required in each country to address the healthcare needs of its rare disease population in an effective way. Whether a single rare disease affects thousands or only a handful of individuals, they all share similar challenges to get a timely diagnosis, face the same barriers to access highly specialized care and treatment options and need to deal with a substantial psychosocial burden.

The health of people living with a rare disease should not be left to luck or chance especially amidst the COVID-19 pandemic. Planning ahead requires all stakeholders to acknowledge their individual responsibility to build a successful pathway from diagnosis to access and at the same time, commit to work together in a much more agile and coordinated way than what we have seen so far. If we fail to do so, we will have failed the 30 million people living with a rare disease in Europe.

The 1st International Conference on Rare Diseases “Building a Pathway from Diagnosis to Access” recognises that the next decade holds great potential for improvement and that while we cannot predict the future, we all have a role in preparing for it. As the EU shapes its future regulations, strategies and access policies, this conference will serve as an opportunity to press the ‘pause button’ and take the time to co-create policy options today that can lead to a better patient journey in the future.

Engaging all stakeholders to take action, the 1st International Conference on Rare Diseases aspires to bring together all stakeholders in the rare disease community – patient representatives, policy makers, clinicians, researchers, industry representatives, payers and regulators to exchange invaluable knowledge with the aim to enhance dialogue and promote policy changes to help build a better pathway from Diagnosis to Access for Rare Diseases.

#EUIndustryWeek2021: The next Industrial Revolution is a Bio Revolution
2021-02-23 11:00 - 12:30 | VIRTUAL, Avenue des Arts 53, Brussels, 1000, Belgium
Global challenges like COVID-19 and climate change require a range of solutions, including those coming from innovative biotechnology. Life sciences and biotechnology is a key industrial sector which can play a transformative role in securing the EU’s competitive edge in health and sustainability.From new treatments for rare diseases to bio-based products, biotechnology can revolutionize our approach to global challenges, paving the way for an industrial revolution driven by the life sciences.

Join EuropaBio for presentations and discussion around the key issues where biotechnology is making a difference and how the scientific and business landscape will enable it in the future.Our panel will discuss the innovation potential of industrial and healthcare biotechnology for long term and future EU competitiveness, including biotech SMEs as a critical part of the EU life sciences ecosystem, and the need for a strategic approach for investment and innovation.Confirmed speakers:

Dr Marcus Remmers, CTO, Royal DSMMr Geoffrey Pot, VP operations, Takeda & bio.be ChairmanProf Isabel Rocha, Pro-Rector of Nova University of LisbonDr Armin Spök, TU Graz, CHIC H2020 Project

This webinar is hosted by EuropaBio under the umbrella of the EU Industry Days and will be moderated by Dr Claire Skentelbery (Director-General, EuropaBio).You can download below the speakers’ presentations:

EU-Industry-Days-EuropaBio-Event-Armin-Spoek-PresentationDownload

EU-Industry-Days-EuropaBio-Event-Geoffrey-Pot-PresentationDownload

EU-Industry-Days-EuropaBio-Event-Isabel-Rocha-PresentationDownload

EU-Industry-Days-EuropaBio-Event-Marcus-Remmers-PresentationDownload

EuropaBio National Associations Council: Brexit Impact for UK and Europe (Member-only webinar)
2021-02-18 11:30 - 13:00
As part of the EuropaBio National Associations Council, this meeting kick starts a long term Brexit monitoring Group within EuropaBio which will support members to understand and manage Brexit changes and for the National Associations Council to identify priority topics for joint communications.

KeyGene’s two-part webinar on PanGenomes: needs, value and applications (part 1)
2021-02-17 16:00 - 17:00

#EUIndustryWeek2021: Bio4Products & Rehap
2021-02-17 13:00 - 17:00
Moving Towards a Competitive European Bioeconomy: Emerging Biorefinery Technologies & Pathways to Deployment

For Europe to move towards a competitive bioeconomy, is it is essential that biorefinery technologies developed in the lab and at pilot scale are upscaled and deployed at an industrial scale. Industry and policy makers must work together to create commercial pathways to this greener future – but how?

This interactive event brings together researchers, industry leaders and policy makers to discuss how the European bioeconomy can take green technology from idea to deployment and who needs to do what to make this happen.

Short agenda:

13:00 Introductions and keynote from the EU

13:30 Technical sessions – project achievements Feedstock, processes and new products Interactive session with audience Q&A

15:00 Coffee break

15:30 First panel session From idea to deployment – an industry view

16:15 Second panel session Rollout of biorefinery technology – policy perspective

The event is organised by two EU-funded SPIRE projects, Bio4Products and Rehap, both successful in identifying biomass availability and developing innovative new conversion processes and bio-based products. The projects have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreements number 723070 and 723670 respectively.

nova Session: Renewable Polymers: Production and Trends 2020-2025 (Member Discount)
2021-02-17 09:00 - 18:00 | VIRTUAL & ON SITE (Cologne), nova-Institut GmbH - Chemiepark Knapsack Industriestraße 300 50354 Germany, Huerth, Azerbaijan
The only way for chemicals and plastics to become sustainable, climate-friendly and part of the circular economy is the complete substitution of fossil carbon with renewable carbon from alternative sources: biomass, CO2 and recycling. Sold out PLA in 2019 has led to the installation of increased capacities in 2020, PE and PP made from bio-based naphtha are breaking ground and future expansion for bio-based polyamides will come into place, growth for bio-based polymers is expected to over 6 % until 2025. Additionally, the use of CO2 as chemical feedstock for polymers has been intensively diversified. Besides the long-established use of CO2 for the synthesis of polycarbonates, also polyurethanes can already be based on it. Optimised technology approaches in fermentation, electrochemistry and catalysts for conversion are emerging and broaden the CO2-based polymer portfolio.

Get the newest market developments for bio-based building blocks and polymers as well as the latest technology developments for CO2-based polymers. Join the nova Session and discuss with the experts. The nova-Institute invites to the nova Session “Renewable Polymers: Production and Trends 2020-2025” on 17 February, 2021. The all-day workshop will be an online event. The workshop will focus on the market report “Bio-based Building Blocks and Polymers –Global Capacities, Production and Trends 2020-2025” and the trend report “Carbon dioxide (CO2) as chemical feedstock for polymers – technologies, polymers, developers and producers” published in January.

The main authors of the report will participate in the workshop and discuss with you. The nova Session offers the unique opportunity to exchange information about current market and technology developments at the highest level.

Participants are welcome to submit their specific topics of interest beforehand or put them up for discussion at the session.

EuropaBio members receive a 20% discount on the registration fee. Please contact Martina Cilia for more information.

VISIT THE WEBSITE

BIOKET 2021
2021-02-01 09:00 - 2021-02-19 18:00 | VIRTUAL & ON SITE (Cologne), nova-Institut GmbH - Chemiepark Knapsack Industriestraße 300 50354 Germany, Huerth, Azerbaijan
Register now

Second International Conference on Cellulose Fibres, the fastest growing fibre group in textiles, the largest investment sector in the bio-based economy and the solution for avoiding microplastics
With 210 participants and 15 exhibitors from 26 different countries, the “1st International Conference on Cellulose Fibres” in 2020 was a great success and exceeded all expectations. The trade press wrote: “nova-Institute hits the mark with new conference”. The focus of the conference was on markets, technologies and sustainability – and especially alternative cellulose feedstocks.
Building on this success, the 2nd International Conference on Cellulose Fibres will again cover the entire value chain from the lignocellulosic feedstock, dissolving pulp, cellulose fibres – such as rayon, viscose, modal or lyocell and new developments, to a wide range of applications, woven textiles (clothing) and non-wovens (wipes and technical applications). All these sectors have significantly gained in dynamics over the last few years.
Cellulose fibres are a success story within the textiles market with a cumulated annual growth rate (CAGR) between 5 and 10% over the last ten years – similar growth rates are expected in the next decade. This makes cellulose fibres the fastest growing fibre group in the textile industry and also the largest investment sector in the bio-based economy worldwide. The challenge now is to achieve a balance between the ongoing capacity expansion and the growing demand – to avoid over capacities, but also to cover the growing demand of the big brands.
The high growth rates are driven by the demand for natural fibres (and bottlenecks in cotton), the microplastic problem and possible bans for plastic fibres. All three drivers will continue to play a significant role in the future development of the sector.

VISIT WEBSITE

2nd International Conference on Cellulose Fibres (Member Discount)
2021-01-30 00:00 - 2021-02-04 23:59 | VIRTUAL & ON SITE (Cologne), nova-Institut GmbH - Chemiepark Knapsack Industriestraße 300 50354 Germany, Huerth, Azerbaijan
Register now

Second International Conference on Cellulose Fibres, the fastest growing fibre group in textiles, the largest investment sector in the bio-based economy and the solution for avoiding microplastics
With 210 participants and 15 exhibitors from 26 different countries, the “1st International Conference on Cellulose Fibres” in 2020 was a great success and exceeded all expectations. The trade press wrote: “nova-Institute hits the mark with new conference”. The focus of the conference was on markets, technologies and sustainability – and especially alternative cellulose feedstocks.
Building on this success, the 2nd International Conference on Cellulose Fibres will again cover the entire value chain from the lignocellulosic feedstock, dissolving pulp, cellulose fibres – such as rayon, viscose, modal or lyocell and new developments, to a wide range of applications, woven textiles (clothing) and non-wovens (wipes and technical applications). All these sectors have significantly gained in dynamics over the last few years.
Cellulose fibres are a success story within the textiles market with a cumulated annual growth rate (CAGR) between 5 and 10% over the last ten years – similar growth rates are expected in the next decade. This makes cellulose fibres the fastest growing fibre group in the textile industry and also the largest investment sector in the bio-based economy worldwide. The challenge now is to achieve a balance between the ongoing capacity expansion and the growing demand – to avoid over capacities, but also to cover the growing demand of the big brands.
The high growth rates are driven by the demand for natural fibres (and bottlenecks in cotton), the microplastic problem and possible bans for plastic fibres. All three drivers will continue to play a significant role in the future development of the sector.

Register now
